Cardiopulmonary indications for endothelin receptor antagonists: review of recent efficacy trials

Bibliography

• YANAGISAWA M, KURIHARA H, KIMURA S et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 332:411–415.
   Google Scholar
• Discovery of ET-1.
   Google Scholar
• GRAY G, WEBB D: The endothelin system and its poten- tial as a therapeutic target in cardiovascular disease. Pharmacol. 7her. (1996) 72(2):109–148.
   Google Scholar
• SAKURAI T, YANAGISAWA M, MASAKI T: Molecular char-acterization of endothelin receptors. Trends Pharmacol Sci. (1992) 13:103–108.
   PubMed Web of Science ®Google Scholar
• TURNER A, MURPHY L: Molecular pharmacology of en-dothelin converting enzymes. Biochem. Pharmacol. (1996) 51:91–102.
   PubMed Web of Science ®Google Scholar
• SHIMADA K, TAKAHASHI M, TANZAWA K: Cloning and functional expression of endothelin-converting en-zyme from rat endothelial cells. J. Biol. Chem. (1994) 269:18275–18278.
   PubMed Web of Science ®Google Scholar
• XU D, EMOTO N, GIAID A et al: ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell (1994) 78:473–485.
   PubMed Web of Science ®Google Scholar
• EMOTO N, YANAGISAWA M: Endothelin-converting en-zyme-2 is a membrane, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J. Biol. Chem. (1995) 270:15262–15268.
   PubMed Web of Science ®Google Scholar
• WARNER T, ELLIOTT J, OHLSTEIN E: 'California dreamin'about endothelin: emerging new therapeutics. Trends Pharmacol. Sci. (1996) 17:177–181.
   PubMed Web of Science ®Google Scholar
• ARIA H, HORI S, ARAMORI I, OHKUBO H, NAKAMICHI S:Cloning and expression of a cDNA encoding an en-dothelin receptor. Nature (1990) 348:730–732
   PubMed Web of Science ®Google Scholar
• HOSODA K, NAKAO K, TAMURA N eta].: Organization, structure, chromosomal assignment, and expression of the gene encoding the human endothelin-A receptor. J. Biol. Chem (1992) 267:18797–18804.
   Google Scholar
• SAKURAI T, YANAGISAWA M, TAKUVVA Y et al: Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature (1990) 348:732–735.
   PubMed Web of Science ®Google Scholar
• ARAI H, NAKAO K, TAKAYA K et aL: The human en-dothelin B receptor gene. Structural organization and chromosomal assignment./ Biol. Chem (1993) 268:3463–3470
   Google Scholar
• MASAKI T, VANE J, VANHOUTTE P: International Unionof Pharmacology nomenclature of endothelin recep-tors. Pharmacol Rev. (1994) 46(2):137–142.
   PubMed Web of Science ®Google Scholar
• WARNER T, ALLCOCK G, CORDER R, VANE J: Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contractions and the release of EDRF. Br. J. Pharmacol (1993) 110:777–782.
   PubMed Web of Science ®Google Scholar
• SUDJARWO S, HORI M, TANAKA T et al: Subtypes of endothelin ETA and ETB receptors mediating venous smooth muscle contractions. Bioc hem. Biophys. Res. Com-mun. (1994) 200:627–633.
   PubMed Web of Science ®Google Scholar
• BATTISTINI B, O'DONNELL L, WARNER T et al.: Charac-terization of endothelin receptors in the isolated gall bladder of the guinea-pig: evidence for an additional ET receptor subtype. Br. J. Pharmacol. (1994) 112:1244–1250.
   Google Scholar
• SHYAMALA V, MOULTHROP T, STRATTON-THOMAS J, TEKAMP-OLSON P: Two distinct human endothelin B receptors generated by alternative splicing from a sin-gle gene. Cell Mol Biol. Res. (1994) 40:285–296.
   PubMedGoogle Scholar
• MIYAMOTO Y, YOSHIMASA T, ARAI H et al: Multipletranscripts of human endothelin-A receptor gene de-tected by reverse transcription and the polymerase chain reaction. J. Cardiovasc. Pharmacol. (1995) 26\(Suppl. 3):S29–S31.
   Google Scholar
• LE MONNIER DE GOUVILLE A, MONDOT S, LIPPTON H, HYMAN A, CAVERO I: Hemodynamic and pharmacologi-cal evaluations of the vasodilator and vasoconstrictor effects of endothelin-1 in rats. J. Pharmacol. Exp. Ther. (1989) 252:300–311.
   Google Scholar
• DOUGLAS S, HILEY C: Endothelium-dependent mesen-teric vasorelaxant effects and systemic actions of en-dothelin (16-21) and other endothelin-related peptides in the rat. Br. J. Pharmacol (1991) 104:311–320.
   PubMed Web of Science ®Google Scholar
• RESINK T, SCOTT-BURDEN T, BUHLER F: Endothelinstimulates phospholipase C in cultured vascular smooth muscle cells. Biochem. Biophys. Res. Commun. (1988) 157:1360–1368.
   PubMed Web of Science ®Google Scholar
• SIMONSON M, DUNN M: The molecular mechanisms ofcardiovascular and renal regulation by endothelin pep-tides. J. Lab. Clin. Med. (1992) 119:622–639.
   PubMed Web of Science ®Google Scholar
• DAVENPORT A, O'REILLY G, KUC R: Endothelin ETA andETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA subtype. Br. J. Pharmacol. (1995) 114:1110–1116.
   PubMed Web of Science ®Google Scholar
• LADOUCEUR D, FLYNN M, KEISER J, REYNOLDS E, HALEENS: ETA and ETB receptors coexist on rabbit pulmonary artery vascular smooth muscle mediating contraction. Biochem. Biophys. Res. Commun. (1993) 196(1)209–215.
   Google Scholar
• HAYNES W, STRACHAN F, WEBB D: Endothelin ETA andETB receptors cause vasoconstriction of human resis-tance and capacitance vessels in vivo. Circulation (1995) 92:357–363.
   PubMed Web of Science ®Google Scholar
• WHITE D, GARRATT H, MUNDIN J eta].: Human sap he-nous vein contains both endothelin ETA and ETB con-tractile receptors. Eur. j Pharmacol. (1994) 257:307–310.
   Google Scholar
• TAKANASHI M, ENDOH M: Concentration and time de-pendence of phosphoinositide hydrolysis induced by endothelin-1 in relation to the positive inotropic effects in the rabbit ventricular myocardium. j Pharmacol Exp. Ther. (1992) 262(3):1189–1194.
   PubMed Web of Science ®Google Scholar
• KARMER B, SMITH T, KELLY R: Endothelin and increased contractility in adult rat ventricular myocytes: role of intracellular alkalosis induced by activation of the pro-tein kinase C dependent Na/H exchanger. Circ. Res. (1991) 68:269–279.
   PubMed Web of Science ®Google Scholar
• MOLENAAR P, O'REILLY G, SHARKEY G et al.: Charac-terization and localization of endothelin receptor sub-types in human atrioventricular conduction system and myocardium. Cir. Res. (1993) 72(3):526–538.
   Google Scholar
• BATTISTINI B, CHAILLER P, D'ORLEANS-JUSTE P, BRIERE N, SIROIS P: Growth regulatory properties of en-dothelins. Peptides (1993) 14:385–399.
   PubMed Web of Science ®Google Scholar
• HASSOUN P, THAPPA V, LANDMAN J, FANBURG B: En-dothelin 1: mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endo-thelial cells. Proc. Soc. Exp. Biol. Med (1992) 199:165–170.
   PubMed Web of Science ®Google Scholar
• JANAKIDEVI K, FISHER A, DEL VECCHIO P et al: En-dothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells. Am. J. Physiol (1992) 263:C1295–C1301.
   PubMed Web of Science ®Google Scholar
• ITO H, HIRATA Y, HIROE M eta].: Endothelin-1 induces hypertrophy with enhanced expression of muscle-spe-cific genes in cultured neonatal rat ca rdiocyt es. Circ. Res. (1991) 69:209–215.
   Google Scholar
• KOMURO I, KURIHARA H, SUGIYAMA T, TAKAKU F, YAZAKI Y: Endothelin stimulates c-fos and c-myc ex-pression and proliferation of vascular smooth muscle cells. FEBS Lett. (1989) 238:249–252.
   Web of Science ®Google Scholar
• WAGNER 0, CHRIST G, WOJTA J eta].: Polar secretion of endothelin-1 by cultured endothelial cells. J. Biol. Chem. (1992) 267:16066–16068.
   Google Scholar
• EGUCHI S, HIRATA Y, IMAI T, MARUMO F: Endothelin-1 as an autocrine growth factor for endothelial cells. J. Cardiovasc. Pharmacol (1995) 26\(Suppl. 3):S297–5283.
   Google Scholar
• BUCHAN K, ALLDUS C, CHRISTODOULOU C et al.: Char-acterization of three non-peptide endothelin receptor ligands using human cloned ETA and ETB receptors. Br. Pharmacol (1994) 112:1251–1257.
   PubMed Web of Science ®Google Scholar
• FUKAMI T, NAGASE T, FUJITA K et al.: Structure-activity relationships of cyclic pentapeptide endothelin A re-ceptor antagonists. J. Med. Chem. (1995) 28:4309–4324.
   Web of Science ®Google Scholar
• ARAMORI I, NIREI H, SHOUBO M eta].: Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected Chinese hamster ovary cells. Mol. Pharmacol (1993) 43:127–131.
   Google Scholar
• ISHIKAWA K, IHARA M, NOGUCHI K eta].: Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc. Nall. Acad. Sci. USA. (1994) 91:4892–4896.
   Google Scholar
• CODY W, DOHERTY A, HE J eta].: The rational design of a highly potent combined ETA and ETB receptors an-tagonist (PD145065) and related analogs. Med. Chem. Res. (1993) 3:154–162.
   Google Scholar
• MASUDA Y, SUGO T, KIKUCHI T eta].: Receptor binding and antagonist properties of a novel endothelin recep-tor antagonist, TAK-044 (cycle[D-a-asparty1-3[(4phenyl-piperazin-1-yOcarbonyl] -L-ala nyl-L-a-aspartyl-D-2- (2-thie ny0 glycyl-L-leucyl-D-tryptophyliclisodium salt), in human endothelin A and endothelin B receptors. J. Pharmacol Exp. Ther. (1996) 279:675–685.
   Google Scholar
• CLOZEL M, BREU V, GRAY G et al.: Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharma-col. Exp. Ther. (1994) 270:228–235.
   PubMed Web of Science ®Google Scholar
• OHLSTEIN E, NAMBI P, DOUGLAS S et al.: SB 209670, arationally designed potent nonpeptide endothelin re-ceptor antagonist. Proc. Nail. Acad. ScL USA (1994) 91:8052–8056.
   PubMed Web of Science ®Google Scholar
• OHLSTEIN E, NAMBI P, LARGO A et al.: Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist]. Pharma-col. Exp. Ther. (1996), 276: 609–15.
   Google Scholar
• DOHERTY A, PATT W, EDMUNDS J eta].: Discovery of a novel series of orally active non-peptide endothelin-A ETA receptor-selective antagonists. J. Med. Chem. (1995) 38:1259–1263.
   Google Scholar
• OPGENORTH T, ADLER A, CALZADILLA S et al.: Pharma-cological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J. Pharmacol. Exp. Ther. (1996) 276:473–481.
   PubMed Web of Science ®Google Scholar
• WU C, RAJU B, OKUN I, STAVROS F, CHAN M: 2-benzyl-carbonylthiophene-3-sulfonamides are orally active ETA selective endothelin antagonists. Book of Abstracts, 211th ACS National Meeting. MEDI-148. New Orleans, LA, (March 24–28, 1996, American Chemical Society, Washington, DC).
   Google Scholar
• RIECHERS H, ALBRECHT H, AMBERG W et al.: Discovery and optimization of a novel class of orally active non-peptidic endothelin-A receptor antagonists. J. Med. Chem. (1996) 39:2123–2128.
   PubMed Web of Science ®Google Scholar
• SHIMOYAMA H, SABBAH H, BORZAK S et al.: Short-termhemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure. Circulation (1996) 94:779–784.
   PubMed Web of Science ®Google Scholar
• SUTSCH G, HUNZIKER P, KIM Jet al: Sustained haemody-namic effects of 2 weeks therapy with the orally active endothelin-receptor antagonist bosentan in severe chronic heart failure despite angiotensin-coverting en-zyme inhibition. ELI!: Heart J. (1996) 17:20 (A–199).
   PubMed Web of Science ®Google Scholar
• ROUX S, LOFFLER B, GRAY G etal: The role of endothelin in experimental cerebral vasospasm. Neurosurgery (1995) 37:78–86.
   PubMed Web of Science ®Google Scholar
• CHEN S-J, CHEN Y-F, MENG Q eta].: Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J. Appl. Physic)]. (1995) 76 (6):2122–2131.
   Google Scholar
• WANG Q, LI X, PERNOW J: The nonpeptide endothelin receptor antagonist bosentan enhances myocardial re-covery and endothelial function during reperfusion of the ischemic rat heart J. Cardiovasc. Pharmacol. (1995) 26\(Suppl. 3):5445–S447.
   Google Scholar
• FILEP J, FOURNIER A, FOELDES-FILEP E: Effects of theETA/ETB receptor antagonist bosentan on endothelin-1-induced myocardial ischemia and edema in the rat. Br. J. Pharmacol (1995) 116:1745–1750.
   PubMed Web of Science ®Google Scholar
• R&D focus database. IMSworld Publications Ltd.
   Google Scholar
• Pharmaprojects PLUS v2.0 database. PJB Publications Ltd., Richmond, Surrey, UK.
   Google Scholar
• WILLETTE R, OHLSTEIN E MITCHELL M et al.: Nonpep tide endothelin receptor antagonists. VIII: Attenuation of acute hypoxia-induced pulmonary hypertension in the dog. J. Pharmacol. Exp. Ther. (1997) 280:695–701.
   Google Scholar
• GELLAI M, JUGUS M, FLETCHER T et al.: Nonpeptide endothelin receptor antagonist. V: Prevention and re-versal of acute renal failure in the rat by SB 209670. J. Pharmacol. Exp. Ther. (1995), 275: 200–206.
   Google Scholar
• BROOKS D, DEPALMA P, GELLAI M et al.: Nonpeptide endothelin receptor antagonist. III: Effect of SB 209670 and BQ 123 on acute renal failure in anesthetized dogs. Pharmacol Exp. Ther. (1994) 271:769–775.
   Google Scholar
• WILLETTE R, ZHANG H, MITCHELL M eta].: Nonpeptide endothelin receptor antagonist: cerebrovascular char-acterization and effects on delayed cerebral vas ospas m. Stroke (1994) 25:2450–2455.
   Google Scholar
• BARONE F, WHITER, ELLIOTT J, FEUERSTEIN G, OHLSTEIN E: The endothelin receptor antagonist SB 217242 re-duces cerebral focal ischemic bra in injury. J. Cardiovasc. Pharmacol. (1995) 26 (Sup pl. 3):S404–S407.
   Google Scholar
• PATEL T, GALBRAITH S, GRAHAM D et al.: Endothelin receptor antagonist increases cerebral perfusion and reduces ischemic damage in feline focal cerebral is-chemia. j Cereb. Blood Flow Metab. (1996) 16:950–958.
   PubMed Web of Science ®Google Scholar
• KEISER J, SCHROEDER R, HALLAK H eta].: Pharmacody-namics of PD 156707, a selective endothelin receptor-A antagonist, in acute hypoxic pulmonary hypertension. FASEB (1997) 11(3):A36 (A-206).
   Google Scholar
• BIALECKI R: Endothelin's pathological role in pulmo-nary hypertension. IBC International Conference on En-dothelin Inhibitors. San Diego, California, USA (Feb. 1996).
   Google Scholar
• MCCONNELL P, WANG W, GALLAGHER K, ZUCKER I: The effects of a specific endothelin-A receptor antagonist on the development of chronic heart failure in the dog. FASEB J (1995) A–2485.
   Google Scholar
• CHEN S-J, OPGENORTH T, VVESSALE J, CHEN Y-F, DICARLO S: A-127722, an orally active antagonist of endothelin-A receptors, prevents short term hypoxia induced pulmo-nary hypertension. Circulation (1995) 92(8):I–323 (A-1535).
   Google Scholar
• BORGESON D, GRANTHAM J, WILLIAMSON E et al.: Func-tional role of endogenous endothelin and the en-dothelin-A receptor in experimental congestive heart failure. Circulation (1996) 94(8 Suppl. 1):I-75 (A–0430).
   Google Scholar
• BROCK T: Therapeutic uses of selective ETA receptor antagonists in vascular diseases. IBC International Con-ference on Endothelin Inhibitors. San Diego, CA, USA (Feb. 1996).
   Google Scholar
• CHENG C-P, SUZUKI M, OHTE N, LITTLE W, WILLIAMS:Effects of endothelin-1 antagonist on coronary flow and left ventricular systolic and diastolic performance dur- ing exercise artery heart failure. Circulation (1996) 94(8 Suppl. 1)1–75 (A–0429).
   Google Scholar
• LOVE M, HAYNES W, GRAY G, VVEBB D, MCMURRAY J:Vasodilator effects of encbthelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibi-tors. Circulation (1996) 94:2131–2137.
   PubMed Web of Science ®Google Scholar
• SAKAI S, MIYAUCHI T, KOBAYASHI M eta].: Inhibition ofmyocardial endothelin pathway improves long-term survival in heart failure. Nature (1996) 384:353–355.
   Google Scholar
• BONVALLET S, ZAMORA M, HASUNUMA K et al: BQ123,an ETA-receptor antagonist, attenuates hypoxic pulmo-nary hypertension in rats. Am. J. Physiol (1994) 266:H1327–H1331.
   PubMed Web of Science ®Google Scholar
• MIYAUCHI T, YORIKANE R, SAKAI S et al.: Contributionof endogenous endothelin-1 to the progression of car-diopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ. Res. (1993) 73:887–897.
   PubMed Web of Science ®Google Scholar
• CLOZEL M, WATANABE H: BQ-123, a peptide endothelinETA antagonist, prevents the early cerebral vasospasm following subarachnoid haemorrhage after intracister-nal but not intravenous injection. Life Sci (1993) 52:825–832.
   PubMed Web of Science ®Google Scholar
• MINO N, KOBAYASHI M, NAKAJIMA A et aL: Protectiveeffect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure in rats. Eur. Pharmacol (1992) 221:77–83.
   PubMed Web of Science ®Google Scholar
• OHNISHI M, WADA A, TSUTOMOTO T et al: Comparisonof therapeutic benefit with an endothelin-A receptor and a mixed endothelin receptor antagonist in heart failure. Circulation (1996) 94(8 Suppl. 1): 1–264 (A–1545).
   Google Scholar
• KOJIMA M, KUSUMOTO K, FUJIWARA S, WATANABE T, FUJINO M: Role of endogenous endothelin in the exten-sion of myocardial infarct size studied with the en-dothelin receptor antagonist, TAK-044. J. Cardiovasc. Pharmacol. (1995) 26\(Suppl. 3):S365–S368.
   Google Scholar
• WATANABE T, AWANE Y, IKEDA S et al.: Pharmacology of a non-selective ETA and ETB receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats. Br. J. PharmacoL (1995) 114:949–954.
   PubMed Web of Science ®Google Scholar
• KUSUMOTO K, KUBO K, KANDORI H et al: Effects of anew endothelin antagonist, TAK-044, on post -ischemic acute renal failure in rats. Life Sci. (1994) 55:301–310.
   PubMed Web of Science ®Google Scholar
• COHN J, ARCHIBALD D, ZIESCHF S et al: Effects of vasodilator therapy on mortality in chronic congestive heart failure. New Engl. J. Merl. (1986) 314:1547–1552.
   PubMed Web of Science ®Google Scholar
• COHN J, JOHNSON G, ZIESCHE S eta].: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. New Engl. J. Med. (1991) 325:303–310.
   Google Scholar
• THE CONSENSUS TRAIL STUDY GROUP: Effects of enalapril on mortality in severe congestive heart fail-ure: results of the Cooperative North Scardinavian Enalipril Survival Study. N. Engl. J. Med. (1987) 316:1429–1435.
   PubMed Web of Science ®Google Scholar
• THE SOLVD INVESTIGATORS: Effects of enalapril onsurvival in patients with reduced left ventricular ejec-tion fractions and congestive heart failure. N. Engl. J. Med. (1991) 325:293–302.
   PubMed Web of Science ®Google Scholar
• LOVE M, MCMURRAY J: Endothelin in congestive heart failure. Basic Res. Cardiol. (1996) 91 (Sup pl. 1):21-29. Recent thorough review of endothelin in congestive heart failure.
   Google Scholar
• KIOWSKI W, SUTSCH G, HUNZIKER G eta].: Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet (1995) 346:732–736.
   Google Scholar
• TREELINK J, LOFFLER B-M, HESS P et al: Role of en-dothelin in the maintenance of blood pressure in con-scious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (Bosen-tan). Circulation (1994) 90:2510–2518.
   Google Scholar
• SPINALE F, WALKER J, MUKHERJEE R et al.: Concomitant endothelin receptor subtype-A blockade during the progression of congestive heart failure has direct and beneficial effects on left ventricular and myocyte func-tion. Circulation (1991) 95:1918–1929.
   Google Scholar
• MICHAEL J, MARKEWITZ B: Endothelins and the lung.
   Google Scholar
• •Am. Resp. Crit. Care Med. (1996) 154:555-581. Recent thorough review of endothelin in pulmonary diseases.
   Google Scholar
• GOLDIE R, KNOTT P, CARR M, HAY W, HENRY P: The endothelins in the pulmonary system. Pulmonary Phar-macol. (1996) 9:69–93.
   PubMedGoogle Scholar
• GIAID A, YANAGISAWA M, LANGLEBEN D et al: Expres-sion of endothelin-1 in the lungs of patients with pulmonary hypertension. New Engl. J. Med. (1993) 328:1732–1739.
   PubMed Web of Science ®Google Scholar
• TSUTAMOTO T, WADA A, MAEDA Y, ADACHI T, KI-NOSHITA M: Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J. Am. Coll. Cardiol. (1994) 23:1427–1433.
   PubMed Web of Science ®Google Scholar
• DICARLO V, CHEN S-J, MENG Q et al: ETA-receptorantagonist prevents and reverses chronic hypoxia-in-duced pulmonary hypertension in rat. Am. J Physiol. (1995) 269:L690–L697.
   PubMed Web of Science ®Google Scholar
• EDDAHIBI S, RAFFESTIN B, CLOZEL M, LEVAME M, ADNOT S: Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am. J. Physiol. (1995) 268:H828–H835.
   PubMed Web of Science ®Google Scholar
• SCHROEDER R, QUENBY-DROWNE, KEISER J, UPRICHARD A, HALEEN S: Endothelin converting enzyme inhibition limits circulating endothelin-1 and prevents pulmo-nary hypertension in response to hypoxia. FASEB (1997). In Press.
   Google Scholar
• GHODSI F, WILL J: Changes in pulmonary structure and function induced by monocrotaline intoxication. Am. J. Physiol. (1981) 240:H149–H155.
   PubMed Web of Science ®Google Scholar
• MANSOOR A, HONDA M, SAIDA K et al: Endothelin induced collagen remodeling in experimental pulmo-nary hypertension. Biochem. Biophys. Res. Commun. (1995) 215:981–986.
   PubMed Web of Science ®Google Scholar
• MATHEW R, ZEBALLOW G, TUN H, GEWITZ M: Role of nitric oxide and endothelin-1 in monocrotaline-in-duced pulmonary hypertension in rats. Cardiovasc. Res. (1995) 30:739–746.
   PubMed Web of Science ®Google Scholar
• HESS P, CLOZEL M, CLOZEL J-P: Telemetry monitoring of pulmonary arterial pressure in freely moving rats. Appl. Physiol. (1996) 81(2):1027–1032.
   PubMed Web of Science ®Google Scholar
• OKADA M, YAMASHITA C, OKADA MA, OKADA K: En-dothelin receptor antagonist in a beagle model of pul-monary hypertension: contribution to possible potential therapy? J. Am. Coll. CardioL (1995) 25:1213–1217.
   PubMed Web of Science ®Google Scholar
• OKADA M. YAMASHITA C, OKADA MA, OKADA K: Role of endothelin-1 in beagles with dehydromonocrotaline-induced pulmonary hypertension. Circulation (1995) 92:114–119.
   PubMed Web of Science ®Google Scholar
• ISHIKAWA S, MIYAUCHI T, SAKAI S et al: Elevated levels of plasma endothelin-1 in young patients with pulmo-nary hypertension caused by congenital heart disease and decreased after successful surgical repair. J. Thorac. Cardiovasc. Surg (1995) 110:271–273.
   PubMed Web of Science ®Google Scholar
• BURROWS F, KLINCK J, RABINOVITCH M, BOHN D: Pul-monary hypertension in children: perioperative man-agement. Can. Anaesth. Soc. J. (1986) 33:606–628.
   PubMedGoogle Scholar
• KOMAI H, HAWORTH S: The effects of cardiopulmonary bypass on the lung. In: Cardiopulmonary Bypass in Neo-nates, Infants and Young Children. Jonas R, Elliott M (Eds.), Butterworth Heinemann Ltd., Oxford, UK (1994):242–262.
   Google Scholar
• KIRSHBOM P, TSUI S, DIBERNARDO L et al: Blockade of endothelin-converting enzyme reduces pulmonary hy-pertension after cardiopulmonary bypass and circula-tory arrest. Surgery (1995) 118:440–445.
   PubMed Web of Science ®Google Scholar
• REDDY V, HENDRICKS-MUNOZ K, RAJASINGHE H et al.: Post-cardiopulmonary bypass pulmonary hyperten-sion in lambs with increased pulmonary blood flow. A role for endothelin-1. Circulation (1997). In Press.
   Google Scholar
• HIRAMATSU T, FORBESS J, MIURA T et al.: Effects of endothelin-1 and endothelin-A receptor antagonist on recovery after hypothermic cardioplegic ischemia in neonatal lamb heart. Circulation (1995) 92\(Suppl. 400-11-404.
   Google Scholar
• CODY J, HAAS G, BINKLEYP, CAPERS Q, KELLEY R: Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation (1992) 85:504–509.
   PubMed Web of Science ®Google Scholar
• SAKAI S, MIYAUCHI T, SAKURAI T et aL: Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of en-dothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lungs in congestive heart failure rats. J. Am. Coll Cardiol (1996) 28:1580–1588.
   Google Scholar